Decay accelerating factor

Paroxysmal nocturnal hemoglobinuria (MIM 311770) Acquired defect in biosynthesis of the GPf structures of decay accelerating factor (DAF) and CD59. 

Add an aliquot of the DSS or BS3 solution to the reaction medium to obtain a final concentration of 0.5-5mM. Note Simons et al. (1999) successfully used a concentration of 0.5 mM BS3 with Madin-Darby canine kidney (MDCK) cells permanently expressing a GPI-anchored form of growth hormone decay accelerating factor (GH-DAF) to crosslink the protein interaction complexes on the cell surfaces. 

Lublin, D. M., and Atkinson, J. P. (1989). Decay-accelerating factor Biochemistry, molecular biology, and function. Annu. Rev. Immunol. 7, 35-58. 

Selvarangan, R., Goluszko, P., Popov, V., Singhal, J., Pham, T., Lublin, D. M., Nowicki, S., and Nowicki, B. (2000). Role of decay-accelerating factor domains and anchorage in internalization of Dr-fimbriated Escherichia coli. Infect. Immun. 68,1391-1399. 

Horta, M.F., Ramalho-Pinto, F.J. and Fatima, M. (1991) Role of human decay-accelerating factor in the evasion of Schistosoma mansoni from the complement-mediated killing in vitro. The Journal of Experimental Medicine 1 74, 1 399-1406. 

Pearce, E.J., Hall, B.F. and Sher, A. (1990) Host-specific evasion of the alternative complement pathway by schistosomes correlates with the presence of a phospholipase C-sensitive surface molecule resembling human decay accelerating factor. The Journal of Immunology 1 44, 2751-2756. 

Fig. 14.1 The life cycle of coxsackievirus B3. CVB3 starts its life cycle by attaching to its receptor CAR and coreceptor DAF. Internalized virus releases its viral RNA, which can be used as the template for translation of polyprotein or transcription by RNA-dependent RNA polymerase 3D to replicate its genome. The polyprotein is self-cleaved by virus-encoded proteases to release structural proteins and nonstructural proteins. Later, structural proteins and viral RNA will assemble into progeny virions to be released from infected cell. Abbreviations CVB3, coxsackievirus B3 DAF, decay accelerating factor CAR, coxsackievirus and adenovirus receptor 3Dpo1, RNA-dependent RNA polymerase.

Nicholson-Weller, A., and Wang, C.E. (1994). Structure and function of decay accelerating factor CD55. J Lab Clin Med 123, 485-491. 

Heine, H., El-Samalouti, V.T., Notzel, C., Pfeiffer, A., Lentschat, A., Kusumoto, S., Schmitz, G., Hamann, L., Ulmer, A.J. CD55/decay accelerating factor is part of the lipopolysaccharide-induced receptor complex. Eur J Immunol 33 (2003) 1399-1408. 

Diaphanous-autoregulatory domain Decay accelerating factor Diacyl glycerol... 

Medof, M.E., Kinoshita, T, Silber, R. and Nussenzweig, V. (1985) Amelioration of lytic abnormalities of paroxysmal nocturnal hemoglobinuria with decay-accelerating factor. Proc. Natl Acad. Sci. U.S.A. 82, 2980-2984. 

Rabesandratana, H., Toutant, J.P, Reggio, H. and Vidal, M. (1998) Decay-accelerating factor (CD55) and membrane inhibitor of reactive lysis (CD59) are released within exosomes during in vitro maturation of reticulocyte. Blood 97, 2573-2580. 

KINOSHITA T, MEDW me, SILBER R, NuSSENZWEIG V. Distribution of decay-accelerating factor in the peripheral blood dnonnal individuals and patients with paroxyanal nocturnal hemoglobinuria JExp Mat 162 75-92,1985. 

Decay accelerating factor 70,000 Dissociates C3bBb and Binding protein C4b2a from host cells... 

---